Mid Yorkshire leads the way with UK-first patient recruited into major cardiology trial | News

Mid Yorkshire Teaching NHS Trust has become the first site in the UK to recruit a patient into a landmark Phase III cardiology clinical trial, marking a significant milestone for both the Trust as a teaching hospital and the wider UK clinical research landscape.

The achievement places Mid Yorkshire at the forefront of cardiovascular research delivery, underlining the Trust’s growing reputation as a centre of excellence for innovation, collaboration and high-quality clinical research.

Phase III trials represent a crucial stage in the development of new treatments, determining whether therapies are safe and effective for wider use. Being selected to recruit the first UK patient into a global trial reflects international confidence in the NHS research system and the expertise of frontline teams.

The milestone follows months of intensive preparation involving clinicians, research nurses, pharmacy teams, trial coordinators, governance specialists and operational staff. Working collaboratively and at pace, the team met the national ambition to open commercial clinical trials within 150 days from regulatory submission to first patient recruitment. This is a target set through the UK Clinical Research Delivery programme and supported by the National Institute for Health and Care Research (NIHR).

For patients, the impact is profound. Early access to cutting-edge treatments through clinical trials offers new hope, particularly for those living with complex cardiovascular conditions. Participation also ensures patients are supported by specialist teams and contribute directly to advancing care for future generations.

As a teaching trust, the hospital plays a vital role in translating research into real-world patient benefits while supporting the development of the next generation of healthcare professionals. Achievements such as this not only enhance learning opportunities for staff and students but also help embed a culture of innovation and evidence-based care across the organisation.

Principal Investigator for the trial Dr Ahmed Sabra, said:
“Recruiting the first UK patient into this important Phase III trial is a fantastic achievement for everyone involved. It reflects the commitment, expertise and teamwork across our Trust. Most importantly, it ensures our patients have early access to potentially life-changing treatments while contributing to research that could benefit thousands more in the future.”

The success highlights the strength of the multidisciplinary team behind the trial. Research nurses, including Ceena Manuel and Leanne Wilkie, have played a key role in guiding patients through every stage of the study, ensuring they are informed, supported and safe throughout their journey.

Trial coordinator Aimee Whitaker oversaw the complex set-up and delivery processes, supported by clinical trials assistant Jessica Wilson and research officer Shreya Jha, who ensured regulatory compliance and smooth study operations.

Behind the scenes, pharmacy teams have ensured the safe handling and preparation of investigational medicines, while pathology and radiology colleagues have provided specialist expertise essential for accurate patient assessment and data collection.

This collective effort has enabled the Trust not only to meet demanding national timelines, but also to contribute to a wider resurgence in UK clinical research. Faster study set-up times are helping to attract international investment and position the UK as a globally competitive destination for life sciences innovation.

A special acknowledgement is given to the patient who has taken part in this study, whose contribution plays a crucial role in advancing knowledge and improving care for others.

This latest milestone reinforces the Trust’s commitment to delivering outstanding research that benefits patients today while supporting the future of healthcare.

 

Picture caption Research Nurse-Ceena Manuel, Clinical Trials assistant-Jessica Wilson, Senior Trial Coordinator- Aimee Whitaker, PATIENT, Research Nurse-Leanne Wilkie and PI-Dr Ahmed Sabra.